
Christian Philip Fischer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2709775/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Recurrent severe invasive pneumococcal disease in an adult with previously unknown hyposplenia. BMC Infectious Diseases, 2015, 15, 171.	2.9	3
2	The Acute Effects of Low-Dose TNF- <i>î±</i> on Glucose Metabolism and <i>î²</i> -Cell Function in Humans. Mediators of Inflammation, 2014, 2014, 1-7.	3.0	21
3	Endurance training enhances skeletal muscle interleukin-15 in human male subjects. Endocrine, 2014, 45, 271-278.	2.3	77
4	Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic lowâ€grade inflammation. Diabetes/Metabolism Research and Reviews, 2013, 29, 463-472.	4.0	54
5	Role of vitamin C and E supplementation on IL-6 in response to training. Journal of Applied Physiology, 2012, 112, 990-1000.	2.5	60
6	Satellite Cells Derived from Obese Humans with Type 2 Diabetes and Differentiated into Myocytes In Vitro Exhibit Abnormal Response to IL-6. PLoS ONE, 2012, 7, e39657.	2.5	55
7	Soluble CD163: a biomarker linking macrophages and insulin resistance. Diabetologia, 2012, 55, 1856-1862.	6.3	86
8	Plasma and Muscle Myostatin in Relation to Type 2 Diabetes. PLoS ONE, 2012, 7, e37236.	2.5	89
9	Effect of antioxidant supplementation on insulin sensitivity in response to endurance exercise training. American Journal of Physiology - Endocrinology and Metabolism, 2011, 300, E761-E770.	3.5	70
10	Antioxidant Supplementation Does Not Alter Endurance Training Adaptation. Medicine and Science in Sports and Exercise, 2010, 42, 1388-1395.	0.4	150
11	Integration of microRNA changes in vivo identifies novel molecular features of muscle insulin resistance in type 2 diabetes. Genome Medicine, 2010, 2, 9.	8.2	225
12	Role of Antioxidant Supplementation on Training-induced IL-6. Medicine and Science in Sports and Exercise, 2010, 42, 20.	0.4	2
13	HSP, Exercise, and Antioxidants. Heat Shock Proteins, 2010, , 243-252.	0.2	0
14	Calprotectin — A Novel Marker of Obesity. PLoS ONE, 2009, 4, e7419.	2.5	105
15	Acute Moderate Elevation of TNF-α Does Not Affect Systemic and Skeletal Muscle Protein Turnover in Healthy Humans. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 294-299.	3.6	26
16	RBPâ€ŧoâ€retinol ratio, but not total RBP, is elevated in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2009, 11, 204-212.	4.4	81
17	Glucose ingestion during endurance training does not alter adaptation. Journal of Applied Physiology, 2009, 106, 1771-1779.	2.5	32
18	Calprotectin is released from human skeletal muscle tissue during exercise. Journal of Physiology, 2008, 586, 3551-3562.	2.9	48

2

CHRISTIAN PHILIP FISCHER

#	Article	IF	CITATIONS
19	Plasma YKL-40. Diabetes, 2008, 57, 3078-3082.	0.6	127
20	Fat-specific Protein 27 Regulates Storage of Triacylglycerol. Journal of Biological Chemistry, 2008, 283, 14355-14365.	3.4	169
21	Tumor Necrosis Factor-α Modulates Humanin VivoLipolysis. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 543-549.	3.6	81
22	Association between Interleukin-15 and Obesity: Interleukin-15 as a Potential Regulator of Fat Mass. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4486-4493.	3.6	169
23	Interleukin-6 Markedly Decreases Skeletal Muscle Protein Turnover and Increases Nonmuscle Amino Acid Utilization in Healthy Individuals. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2851-2858.	3.6	93
24	Altered regulation of the PINK1 locus: a link between type 2 diabetes and neurodegeneration?. FASEB Journal, 2007, 21, 3653-3665.	0.5	83
25	PGC-1β is downregulated by training in human skeletal muscle: no effect of training twice every second day vs. once daily on expression of the PGC-1 family. Journal of Applied Physiology, 2007, 103, 1536-1542.	2.5	48
26	Physiological roles of muscle-derived interleukin-6 in response to exercise. Current Opinion in Clinical Nutrition and Metabolic Care, 2007, 10, 265-271.	2.5	167
27	Beneficial health effects of exercise – the role of IL-6 as a myokine. Trends in Pharmacological Sciences, 2007, 28, 152-156.	8.7	283
28	Role of myokines in exercise and metabolism. Journal of Applied Physiology, 2007, 103, 1093-1098.	2.5	613
29	Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia, 2007, 50, 431-438.	6.3	571
30	Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Reply to Lambert GW et al (letter). Diabetologia, 2007, 50, 2029-2030.	6.3	7
31	Associations between insulin resistance and TNF-α in plasma, skeletal muscle and adipose tissue in humans with and without type 2 diabetes. Diabetologia, 2007, 50, 2562-2571.	6.3	137
32	Vitamin E isoform-specific inhibition of the exercise-induced heat shock protein 72 expression in humans. Journal of Applied Physiology, 2006, 100, 1679-1687.	2.5	77
33	Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scandinavian Journal of Medicine and Science in Sports, 2006, 17, 061120070736003-???.	2.9	162
34	Interleukin-6 in acute exercise and training: what is the biological relevance?. Exercise Immunology Review, 2006, 12, 6-33.	0.4	496
35	Interleukin-6 Infusion During Human Endotoxaemia Inhibits In Vitro Release of the Urokinase Receptor from Peripheral Blood Mononuclear Cells. Scandinavian Journal of Immunology, 2005, 61, 197-206.	2.7	23
36	Effect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscle. Journal of Applied Physiology, 2005, 99, 2075-2079.	2.5	136

#	Article	IF	CITATIONS
37	Interleukinâ€6 receptor expression in contracting human skeletal muscle: regulating role of ILâ€6. FASEB Journal, 2005, 19, 1181-1183.	0.5	56
38	Skeletal muscle adaptation: training twice every second day vs. training once daily. Journal of Applied Physiology, 2005, 98, 93-99.	2.5	228
39	Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clinical Immunology, 2005, 117, 152-160.	3.2	104
40	Interleukin-6 Is a Novel Factor Mediating Glucose Homeostasis During Skeletal Muscle Contraction. Diabetes, 2004, 53, 1643-1648.	0.6	352
41	The metabolic role of IL-6 produced during exercise: is IL-6 an exercise factor?. Proceedings of the Nutrition Society, 2004, 63, 263-267.	1.0	211
42	Endurance training reduces the contraction-induced interleukin-6 mRNA expression in human skeletal muscle. American Journal of Physiology - Endocrinology and Metabolism, 2004, 287, E1189-E1194.	3.5	124
43	Supplementation with vitamins C and E inhibits the release of interleukinâ€6 from contracting human skeletal muscle. Journal of Physiology, 2004, 558, 633-645.	2.9	216
44	Searching for the exercise factor: is IL-6 a candidate?. Journal of Muscle Research and Cell Motility, 2003, 24, 113-119.	2.0	416
45	IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans. American Journal of Physiology - Endocrinology and Metabolism, 2003, 285, E433-E437.	3.5	837
46	Interleukin-6 Stimulates Lipolysis and Fat Oxidation in Humans. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3005-3010.	3.6	609
47	Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochemical and Biophysical Research Communications, 2003, 310, 550-554.	2.1	109
48	Acute interleukin-6 administration does not impair muscle glucose uptake or whole-body glucose disposal in healthy humans. Journal of Physiology, 2003, 548, 631-638.	2.9	106
49	IL-6 activates HSP72 gene expression in human skeletal muscle. Biochemical and Biophysical Research Communications, 2002, 296, 1264-1266.	2.1	40
50	Preferential loss of large neocortical neurons during HIV infection: a study of the size distribution of neocortical neurons in the human brain. Brain Research, 1999, 828, 119-126.	2.2	30